CN114394942A - 酪氨酸激酶抑制剂及其药物应用 - Google Patents
酪氨酸激酶抑制剂及其药物应用 Download PDFInfo
- Publication number
- CN114394942A CN114394942A CN202210197875.XA CN202210197875A CN114394942A CN 114394942 A CN114394942 A CN 114394942A CN 202210197875 A CN202210197875 A CN 202210197875A CN 114394942 A CN114394942 A CN 114394942A
- Authority
- CN
- China
- Prior art keywords
- tyrosine kinase
- fluoro
- kinase inhibitor
- methoxy
- aminoquinazoline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 title claims abstract description 23
- 239000005483 tyrosine kinase inhibitor Substances 0.000 title claims abstract description 19
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 title claims abstract description 15
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims abstract description 15
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims abstract description 15
- -1 amino, substituted amino Chemical group 0.000 claims description 26
- 238000002360 preparation method Methods 0.000 claims description 19
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 7
- 229910052794 bromium Inorganic materials 0.000 claims description 5
- 229910052801 chlorine Inorganic materials 0.000 claims description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims description 5
- 239000001257 hydrogen Substances 0.000 claims description 5
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical compound [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 claims description 5
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 4
- 230000002018 overexpression Effects 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 125000000304 alkynyl group Chemical group 0.000 claims description 3
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims description 3
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims description 3
- 229910052731 fluorine Inorganic materials 0.000 claims description 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 2
- 125000003647 acryloyl group Chemical group O=C([*])C([H])=C([H])[H] 0.000 claims description 2
- 125000003342 alkenyl group Chemical group 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 150000002367 halogens Chemical class 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 125000005017 substituted alkenyl group Chemical group 0.000 claims description 2
- 125000004426 substituted alkynyl group Chemical group 0.000 claims description 2
- 229940124530 sulfonamide Drugs 0.000 claims description 2
- 150000003456 sulfonamides Chemical class 0.000 claims description 2
- 229910052717 sulfur Inorganic materials 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 7
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 abstract description 7
- 125000000524 functional group Chemical group 0.000 abstract description 5
- 230000002401 inhibitory effect Effects 0.000 abstract description 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 abstract description 3
- 235000018417 cysteine Nutrition 0.000 abstract description 3
- 238000007344 nucleophilic reaction Methods 0.000 abstract description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 48
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 42
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- 238000001914 filtration Methods 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- 229960002584 gefitinib Drugs 0.000 description 9
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 230000035772 mutation Effects 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 7
- 235000019341 magnesium sulphate Nutrition 0.000 description 7
- 102000001301 EGF receptor Human genes 0.000 description 6
- 108060006698 EGF receptor Proteins 0.000 description 6
- 235000019270 ammonium chloride Nutrition 0.000 description 5
- 239000012043 crude product Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- LSTRKXWIZZZYAS-UHFFFAOYSA-N 2-bromoacetyl bromide Chemical compound BrCC(Br)=O LSTRKXWIZZZYAS-UHFFFAOYSA-N 0.000 description 4
- UYQMNEZWVKRWMS-UHFFFAOYSA-N 4-chloro-7-fluoro-6-nitroquinazoline Chemical compound N1=CN=C2C=C(F)C([N+](=O)[O-])=CC2=C1Cl UYQMNEZWVKRWMS-UHFFFAOYSA-N 0.000 description 4
- QRZFUQFQXCRJRR-UHFFFAOYSA-N 4-n-(3-chloro-4-fluorophenyl)-7-methoxyquinazoline-4,6-diamine Chemical compound C=12C=C(N)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 QRZFUQFQXCRJRR-UHFFFAOYSA-N 0.000 description 4
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 4
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 4
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 239000012046 mixed solvent Substances 0.000 description 4
- CJOJDNRJDBWZKM-UHFFFAOYSA-N n-(3-chloro-4-fluorophenyl)-7-fluoro-6-nitroquinazolin-4-amine Chemical compound N1=CN=C2C=C(F)C([N+](=O)[O-])=CC2=C1NC1=CC=C(F)C(Cl)=C1 CJOJDNRJDBWZKM-UHFFFAOYSA-N 0.000 description 4
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 3
- 239000004473 Threonine Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 229940121647 egfr inhibitor Drugs 0.000 description 3
- VKEKKVCWODTGAP-UHFFFAOYSA-N n-(3-chloro-4-fluorophenyl)-7-methoxy-6-nitroquinazolin-4-amine Chemical compound C=12C=C([N+]([O-])=O)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 VKEKKVCWODTGAP-UHFFFAOYSA-N 0.000 description 3
- DFMCIAKKWVZERJ-UHFFFAOYSA-N n-(3-ethynylphenyl)-7-methoxy-6-nitroquinazolin-4-amine Chemical compound C=12C=C([N+]([O-])=O)C(OC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 DFMCIAKKWVZERJ-UHFFFAOYSA-N 0.000 description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- QWCPLFGTECZEDQ-UHFFFAOYSA-N 4-n-(3-chloro-4-fluorophenyl)-7-prop-2-ynoxyquinazoline-4,6-diamine Chemical compound N1=CN=C2C=C(OCC#C)C(N)=CC2=C1NC1=CC=C(F)C(Cl)=C1 QWCPLFGTECZEDQ-UHFFFAOYSA-N 0.000 description 2
- GXTDIHSVUDHDCI-UHFFFAOYSA-N 4-n-(3-ethynylphenyl)-7-methoxyquinazoline-4,6-diamine Chemical compound C=12C=C(N)C(OC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 GXTDIHSVUDHDCI-UHFFFAOYSA-N 0.000 description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 2
- 101800003838 Epidermal growth factor Proteins 0.000 description 2
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 2
- 206010027406 Mesothelioma Diseases 0.000 description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 206010038389 Renal cancer Diseases 0.000 description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 229940116977 epidermal growth factor Drugs 0.000 description 2
- 229960001433 erlotinib Drugs 0.000 description 2
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- WWAUZVQBHVPZAZ-UHFFFAOYSA-N n-(3-chloro-4-fluorophenyl)-6-nitro-7-prop-2-ynoxyquinazolin-4-amine Chemical compound N1=CN=C2C=C(OCC#C)C([N+](=O)[O-])=CC2=C1NC1=CC=C(F)C(Cl)=C1 WWAUZVQBHVPZAZ-UHFFFAOYSA-N 0.000 description 2
- LXAQXVGQGJGMAA-UHFFFAOYSA-N n-(3-ethynylphenyl)-7-fluoro-6-nitroquinazolin-4-amine Chemical compound N1=CN=C2C=C(F)C([N+](=O)[O-])=CC2=C1NC1=CC=CC(C#C)=C1 LXAQXVGQGJGMAA-UHFFFAOYSA-N 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 201000010174 renal carcinoma Diseases 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- SUBJHSREKVAVAR-UHFFFAOYSA-N sodium;methanol;methanolate Chemical compound [Na+].OC.[O-]C SUBJHSREKVAVAR-UHFFFAOYSA-N 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- MGAXYKDBRBNWKT-UHFFFAOYSA-N (5-oxooxolan-2-yl)methyl 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OCC1OC(=O)CC1 MGAXYKDBRBNWKT-UHFFFAOYSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- YSEMCVGMNUUNRK-UHFFFAOYSA-N 3-chloro-4-fluoroaniline Chemical compound NC1=CC=C(F)C(Cl)=C1 YSEMCVGMNUUNRK-UHFFFAOYSA-N 0.000 description 1
- QEYMMOKECZBKAC-UHFFFAOYSA-N 3-chloropropanoic acid Chemical compound OC(=O)CCCl QEYMMOKECZBKAC-UHFFFAOYSA-N 0.000 description 1
- NNKQLUVBPJEUOR-UHFFFAOYSA-N 3-ethynylaniline Chemical compound NC1=CC=CC(C#C)=C1 NNKQLUVBPJEUOR-UHFFFAOYSA-N 0.000 description 1
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 1
- VTUAEMSZEIGQRM-UHFFFAOYSA-N 7-fluoro-6-nitro-1h-quinazolin-4-one Chemical compound N1C=NC(=O)C2=C1C=C(F)C([N+](=O)[O-])=C2 VTUAEMSZEIGQRM-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 101500025419 Homo sapiens Epidermal growth factor Proteins 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 229960001686 afatinib Drugs 0.000 description 1
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 229960003005 axitinib Drugs 0.000 description 1
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000007350 electrophilic reaction Methods 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 229940116978 human epidermal growth factor Drugs 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- AHLKSOXEVRYIRD-UHFFFAOYSA-N n-phenylquinazolin-2-amine Chemical class N=1C=C2C=CC=CC2=NC=1NC1=CC=CC=C1 AHLKSOXEVRYIRD-UHFFFAOYSA-N 0.000 description 1
- GVUGOAYIVIDWIO-UFWWTJHBSA-N nepidermin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C(C)C)C(C)C)C1=CC=C(O)C=C1 GVUGOAYIVIDWIO-UFWWTJHBSA-N 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- TVDSBUOJIPERQY-UHFFFAOYSA-N prop-2-yn-1-ol Chemical compound OCC#C TVDSBUOJIPERQY-UHFFFAOYSA-N 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003246 quinazolines Chemical class 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000006965 reversible inhibition Effects 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 150000003587 threonine derivatives Chemical class 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/93—Sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
技术领域
本发明涉及一种酪氨酸激酶抑制剂,及其在抑制和治疗由于酪氨酸激酶过度表达引起的疾病的治疗药物中的应用。
背景技术
细胞内有许多信号通路***,它们相互作用来控制细胞的增殖、生长、转移和凋亡。酪氨酸激酶在信号传导中起关键作用,人类表皮生长因子(EGF)和表皮生长因子受体(EGFR)结合,可以激活酪氨酸激酶的活性,导致表皮生长因子在人类多种实体肿瘤中过度表达,引起不可控制的细胞***,酪氨酸激酶抑制剂(Tyrosine Kinase Inhibitors,TKI)可以阻止和控制酪氨酸激酶的活性,控制细胞的增殖。它的作用机制是与三磷酸腺苷(ATP)竞争激酶的ATP结合位点,相对于传统的细胞毒抗癌药物具有高选择性和不良反应少的特点,在慢性粒细胞白血病(CML)、胃肠间质瘤(GIST)、非小细胞肺癌(NSCLC)、肝细胞癌(HCC)和肾癌(RCC)等疾病的治疗中都表现出优越性。
目前已开发出多种EGFR酪氨酸激酶抑制剂作为抗肿瘤的药物,第一代表酪氨酸激酶抑制剂,吉非替尼和厄洛替尼对于复发和进展期非小细胞肺癌具有良好疗效。它们属于苯胺喹唑啉类化合物,主要作用于EGFR,为了提高活性一般采用以下形式对结构进行改造:在苯胺3位取代基添加亲脂性取代基,如引入乙炔基,或将苯胺上的H替换为F、Cl、Br或I原子;在喹唑啉环的6、7位连接上电子基团;在喹唑啉环的7位取代位置引入N或O原子。目前上市的各种含喹唑啉基团的酪氨酸激酶抑制剂的结构均符合以上构效关系。
我国患者EGFR突变比例较高,对EGFR-TKI治疗敏感。但是耐药性的存在是临床上面临的巨大挑战,几乎所有治疗有效的患者在经过一段时间的缓解期后又出现疾病进展。
EGFR突变多发生于基因外显子18、19、20、21,其中与EGFR-TKI敏感性相关的主要是位于外显子18、21的点突变和外显子19的缺失突变。临床研究显示外显子19、21突变约占酪氨酸激酶区域突变的90%;对含有这些突变的患者,吉非替尼有很好的疗效。
T790M是由于EGFR外显子20的第2369位的胞嘧啶(C)转化为胸腺嘧啶(T),从而导致第790位的编码产物由苏氨酸替换为甲硫氨酸,这个替代与吉非替尼或者厄洛替尼的耐药性有关。苏氨酸作为“看门人基团”位于酪氨酸激酶接触反应核心之外,与吉非替尼的苯胺基团形成具有高度亲和力的氢键,从而保证了药物与酪氨酸激酶紧密结合而发挥抗肿瘤作用;一旦发生突变,苏氨酸被甲硫氨酸取代,使得该位点上引入了一条更大的氨基酸侧链构成空间位阻,从而影响酪氨酸激酶与吉非替尼之间氢键的形成,最终导致吉非替尼无法与其相结合。
第一代酪氨酸激酶抑制剂都是以可逆性抑制(氢键形成)的方式发挥作用,所以一般来说选择性不够好,药效不够强烈和持久,容易引起耐药性。第二代(如阿法替尼)和第三代(如奥希替尼)酪氨酸激酶抑制剂属于不可逆TKI,通常保持可逆性TKI的基本结构骨架,在合适的位置连接上一个亲电的功能团,如α,β-不饱和醛/酮、丙烯酰胺或炔基,这个亲电的功能团可以与ATP结合域附近的半胱氨酸上巯基(富电子的亲核结构)发生亲电反应形成共价键。与可逆性TKI相比,不可逆性TKI具有诸多独特的优势。
发明内容
本发明所要解决的技术问题是,提供一种酪氨酸激酶抑制剂,能够不可逆地抑制酪氨酸激酶活性,抑制和治疗由于酪氨酸激酶过度表达引起的疾病。
实现本发明第一目的的技术方案是一种酪氨酸激酶抑制剂,是一种喹唑啉衍生物,结构式如下:
其中R1选自含有一个碳至六个碳的烷基,烯基,取代烯基,炔基,取代炔基,
R2、R3选自卤素,氢,氨基,取代氨基,氰基,羟基,磺酸基,磺酰胺基,三氟甲基,2,2,2-三氟乙基,甲基,甲氧基,乙炔基;R2、R3的位置可以是邻位、对位或间位。
Y为NH,O,S,Z-N,其中Z选自甲基,乙基,异丙基,三氟甲基,2,2,2-三氟乙基,环丙基。
X选自Cl,Br,F。
n代表0-6的一个整数。
作为可选的,R1为甲基,R2为F,R3为Cl,Y为NH,X为Br,n=0;该酪氨酸激酶抑制剂为4-(4-氟-3-氯苯氨基)-7-甲氧基-6-(N-溴乙酰基)氨基喹唑啉。
实现本发明第二目的的技术方案是上述酪氨酸激酶抑制剂在制备抑制和治疗因酪氨酸激酶过表达所致疾病的治疗药物中的应用。
本发明的酪氨酸激酶抑制剂活性成分在喹唑啉结构的基础上引入含有XCH2(CH2)nC=O的官能团(X为卤素原子,n代表0-6的一个整数),它很容易通过亲核反应与半胱氨酸巯基结合,形成共价键,从而不可逆地抑制酪氨酸激酶活性。
附图说明
图1是实施例1制备得到化合物的核磁共振H谱图。
图2是平板克隆实验分析预处理后间皮瘤40L细胞增殖情况的统计图表。
具体实施方式
本发明的喹唑啉衍生物制备的基本反应过程如下:
以下面结合具体实施例对本发明作进一步说明:
(实施例1)
制备4-(4-氟-3-氯苯氨基)-7-甲氧基-6-(N-溴乙酰基)氨基喹唑啉,步骤如下:
(1)制备4-氯-7-氟-6硝基喹唑啉。
在250毫升圆底瓶中加入4-羟基-7-氟-6硝基喹唑啉8.5克和三氯氧磷150毫升,混合物在搅拌下加热回流6小时。旋转蒸化去掉过量的三氯氧磷,然后用10:1的石油醚/乙酸乙酯洗涤,得固体4-氯-7-氟-6硝基喹唑啉8克,MS(m/z):227.78(M+1)+。
(2)制备4-(4-氟-3-氯苯氨基)-7-氟-6-硝基喹唑啉。
4-氯-7-氟-6硝基喹唑啉2.3克,4-氟-3-氯苯胺1.6克,碳酸钾1.73克加入N,N二甲基甲酰胺30毫升,混合物搅拌加热到50度,10小时后,在减压蒸馏下除去溶剂,加入乙酸乙酯100毫升,用30毫升水洗涤,分离出乙酸乙酯并用硫酸镁干燥。过滤浓缩,残余物用二氯甲烷/甲醇过柱分离,得产物4-(4-氟-3-氯苯氨基)-7-氟-6-硝基喹唑啉3.0克,MS(m/z):336.80(M+1)+。
(3)制备4-(4-氟-3-氯苯氨基)-7-甲氧基-6-硝基喹唑啉。
4-(4-氟-3-氯苯氨基)7-氟-6-硝基喹唑啉3.3克溶解于四氢呋喃100毫升,加入25%甲醇钠甲醇溶液5毫升,室温搅拌8小时,加水50毫升,用乙酸乙酯100毫升萃取,分离出乙酸乙酯并用硫酸镁干燥。过滤浓缩,残余物用二氯甲烷/甲醇过柱分离,得产物4-(4-氟-3-氯苯氨基)-7-甲氧基-6-硝基喹唑啉2.5克,MS(m/z):348.72(M+1)+。
(4)制备4-(4-氟-3-氯苯氨基)-7-甲氧基-6-氨基喹唑啉。
4-(4-氟-3-氯苯氨基)7-甲氧基-6-硝基喹唑啉3.3克溶解于混合溶剂乙醇150毫升和水8毫升,加入氯化铵1.6克和铁粉2.8克,然后在搅拌下加热回流5小时。过滤浓缩滤液,得到的固体用15毫升水洗涤除出氯化铵,过滤干燥得产物2.6克,MS(m/z):318.74(M+1)+。
(5)制备4-(4-氟-3-氯苯氨基)-7-甲氧基-6-(N-溴乙酰基)氨基喹唑啉。
4-(4-氟-3-氯苯氨基)7-甲氧基-6-氨基喹唑啉160毫克和三乙胺129毫克溶解于二氯甲烷50毫升,然后冷却至0度,慢慢滴加溴乙酰溴120毫克,搅拌3小时,加水10毫升,分离出二氯甲烷并用无水硫酸镁干燥,过滤浓缩得粗产品,进一步过柱纯化得产物170毫克。
所制得化合物的表征如下:MS(m/z):438.80(M+1)+。
核磁共振氢谱图见图1。
H NMR(CD3OD/DMSO-D6):δ=8.92(s,1H),8.55(s,1H),8.12(m,1H),7.79(m,1H),7.38(m,1H),7.30(s,1H),4.28(s,2H),4.06(s,3H)。
另外,图中δ=4.04是H2O的峰,3.13是MeOH的峰,2.60是DMSO的峰。
(实施例2)
制备4-(4-氟-3-氯苯氨基)-7-甲氧基-6-(N-氯乙酰基)氨基喹唑啉,步骤如下:
4-(4-氟-3-氯苯氨基)-7-甲氧基-6-氨基喹唑啉160毫克和三乙胺129毫克溶解于二氯甲烷50毫升,然后冷却至0度,慢慢滴加氯乙酰氯68毫克,搅拌5小时,加水10毫升,分离出二氯甲烷并用无水硫酸镁干燥,过滤浓缩得粗产品,进一步过柱纯化得产物120毫克,MS(m/z):394.68(M+1)+。
(实施例3)
制备4-(4-氟-3-氯苯氨基)-7-甲氧基-6-(N-3‘-氯丙酰基)氨基喹唑啉,步骤如下:
4-(4-氟-3-氯苯氨基)-7-甲氧基-6-氨基喹唑啉160毫克和对二甲氨基吡啶60毫克溶解于N,N-二甲基甲酰胺10毫升,加入1-乙基-(3-二甲基氨基丙基)碳酰二亚胺盐酸盐125毫克,3-氯丙酸70毫克和N,N-二异丙基乙基胺129毫克,搅拌15小时,加水20毫升,用乙酸乙酯100毫升萃取,分离出乙酸乙酯并用硫酸镁干燥。过滤浓缩,残余物用二氯甲烷/甲醇过柱分离,得产物4-(4-氟-3-氯苯氨基)-7-甲氧基-6-(N-3‘-氯丙酰基)氨基喹唑啉55毫克,MS(m/z):408.68(M+1)+。
(实施例4)
制备4-(4-氟-3-氯苯氨基)-7-炔丙基氧基-6-(N-溴乙酰基)氨基喹唑啉,步骤如下:
(1)制备4-(4-氟-3-氯苯氨基)-7-炔丙基氧基-6-硝基喹唑啉。
炔丙醇6.0克溶解于四氢呋喃300毫升,分批慢慢加入氢化钠4.3克,室温搅拌1小时,然后加入4-(4-氟-3-氯苯氨基)-7-氟-6-硝基喹唑啉13克。继续室温搅拌5小时,向反应液加水100毫升,再用乙酸乙酯300毫升萃取,分离出乙酸乙酯并用硫酸镁干燥。过滤浓缩,得产物4-(4-氟-3-氯苯氨基)-7-炔丙基氧基-6-硝基喹唑啉2.5克,MS(m/z):372.75(M+1)+。
(2)制备4-(4-氟-3-氯苯氨基)-7-炔丙基氧基-6-氨基喹唑啉。
4-(4-氟-3-氯苯氨基)-7-炔丙基氧基-6-硝基喹唑啉10.0克溶解于混合溶剂乙醇250毫升和水18毫升,加入氯化铵4.5克和铁粉7.0克,然后在搅拌下加热回流15小时。过滤浓缩滤液,得到的固体进一步过柱纯化得产物7.6克,MS(m/z):342.76(M+1)+。
(3)制备4-(4-氟-3-氯苯氨基)-7-炔丙基氧基-6-(N-溴乙酰基)氨基喹唑啉。
4-(4-氟-3-氯苯氨基)-7-炔丙基氧基-6-氨基喹唑啉343毫克和三乙胺258毫克溶解于二氯甲烷100毫升,然后冷却至0度,慢慢滴加溴乙酰溴220毫克,搅拌3小时,加水20毫升,分离出二氯甲烷并用无水硫酸镁干燥,过滤浓缩得粗产品,进一步过柱纯化得产物300毫克,MS(m/z):462.69(M+1)+。
(实施例5)
制备4-(4-氟-3-氯苯氨基)-7-苯酚基-6-(N-氯乙酰基)氨基喹唑啉,步骤如下:
(1)制备4-(4-氟-3-氯苯氨基)-7-苯酚基-6-硝基喹唑啉。
4-(4-氟-3-氯苯氨基)-7-氟-6-硝基喹唑啉2.0克溶解于四氢呋喃100毫升,加入苯酚钠2.2克,室温搅拌2小时,加水50毫升,用乙酸乙酯100毫升萃取,分离出乙酸乙酯并用硫酸镁干燥。过滤浓缩,残余物用二氯甲烷/甲醇过柱分离,得产物4-(4-氟-3-氯苯氨基)7-苯酚基-6-硝基喹唑啉1.5克,MS(m/z):410.79(M+1)+。
(2)制备4-(4-氟-3-氯苯氨基)-7-苯酚基-6-氨基喹唑啉。
4-(4-氟-3-氯苯氨基)-7-苯酚基-6-硝基喹唑啉1.5克溶解于混合溶剂乙醇100毫升和水6毫升,加入氯化铵2.0克和铁粉2.8克,然后在搅拌下加热回流5小时。过滤浓缩滤液,得到的固体用15毫升水和20毫升***洗涤,干燥得产物1.0克,MS(m/z):380.81(M+1)+。
(3)制备4-(4-氟-3-氯苯氨基)-7-苯酚基-6-(N-氯乙酰基)氨基喹唑啉。
4-(4-氟-3-氯苯氨基)-7-苯酚基-6-氨基喹唑啉160毫克和三乙胺129毫克溶解于二氯甲烷50毫升,然后冷却至0度,慢慢滴加溴乙酰溴120毫克,搅拌3小时,加水10毫升,分离出二氯甲烷并用无水硫酸镁干燥,过滤浓缩得粗产品,进一步过柱纯化得产物170毫克,MS(m/z):456.74(M+1)+。
(实施例6)
制备4-(3-乙炔基苯氨基)-7-甲氧基-6-(N-溴乙酰基)氨基喹唑啉,步骤如下:
(1)制备4-(3-乙炔基苯氨基)-7-氟-6-硝基喹唑啉。
4-氯-7-氟-6硝基喹唑啉2.3克,3-乙炔基苯胺1.3克,碳酸钾1.73克溶于N,N二甲基甲酰胺30毫升,混合物搅拌加热到50度,10小时后,在减压蒸馏下除去溶剂,加入乙酸乙酯100毫升,用30毫升水洗涤,分离出乙酸乙酯并用硫酸镁干燥。过滤浓缩,残余物用二氯甲烷/甲醇过柱分离,得产物4-(3-乙炔基苯氨基7)-氟-6-硝基喹唑啉2.1克,MS(m/z):308.68(M+1)+。
(2)制备4-(3-乙炔基苯氨基)-7-甲氧基-6-硝基喹唑啉。
4-(3-乙炔基苯氨基)7-氟-6-硝基喹唑啉1.3克溶解于四氢呋喃100毫升,加入25%甲醇钠甲醇溶液5毫升,室温搅拌8小时,加水50毫升,用乙酸乙酯100毫升萃取,分离出乙酸乙酯并用硫酸镁干燥。过滤浓缩,残余物用二氯甲烷/甲醇过柱分离,得产物4-(3-乙炔基苯氨基)7-甲氧基-6-硝基喹唑啉0.8克,MS(m/z):320.70(M+1)+。
(3)制备4-(3-乙炔基苯氨基)-7-甲氧基-6-氨基喹唑啉。
4-(3-乙炔基苯氨基)-7-甲氧基-6-硝基喹唑啉0.8克溶解于混合溶剂乙醇50毫升和水5毫升,加入氯化铵0.6克和铁粉1.1克,然后在搅拌下加热回流5小时。过滤浓缩滤液,得到的固体用10毫升水洗涤除出氯化铵,过滤干燥得产物0.5克,MS(m/z):290.80(M+1)+。
(4)制备4-(3-乙炔基苯氨基)-7-甲氧基-6-(N-溴乙酰基)氨基喹唑啉。
4-(3-乙炔基苯氨基)-7-甲氧基-6-氨基喹唑啉145毫克和三乙胺129毫克溶解于二氯甲烷50毫升,然后冷却至0度,慢慢滴加溴乙酰溴120毫克,搅拌3小时,加水10毫升,分离出二氯甲烷并用无水硫酸镁干燥,过滤浓缩得粗产品,进一步过柱纯化得产物105毫克,MS(m/z):410.84(M+1)+。
(试验例1)
对实施例1制备的化合物与吉非替尼进行对比检测,结果如下:
一、细胞平板克隆实验检测细胞增殖情况
1.实验步骤:
(1)用30μM的吉非替尼和实施例1药物分别预处理间皮瘤细胞系40L,用PBS作为空白对照组;
(2)收集不同处理组后的40L细胞;显微镜下计数,用相应的完全培养基调整细胞数量为200个/孔(2mL)种于六孔板中,在37℃含5%CO2培养箱内培养;
(3)每隔3天换一次新鲜完全培养基;
(4)约连续培养7-10天,弃去培养液,用1×PBS小心洗涤3遍,每个培养皿中加入1mL4%多聚甲醛固定细胞30分钟,弃去多聚甲醛,再次用1×PBS洗涤3遍,在室温下用结晶紫染色10分钟,弃去染液,1×PBS洗涤3遍;
(5)用相机拍照并计数统计分析。
2.实验结果
通过平板克隆实验分析不同药物对40L细胞的增殖能力影响,经过10天的实验结果如图2所示,图中**P<0.01,****P<0.0001。显示实施例1药物表现出具有显著优于吉非替尼的抑制肿瘤细胞增殖的能力。
Claims (3)
2.根据权利要求1所述的酪氨酸激酶抑制剂,其特征在于:R1为甲基,R2为F,R3为Cl,Y为NH,X为Br,n=0。
3.权利要求1所述的酪氨酸激酶抑制剂在制备抑制和治疗因酪氨酸激酶过表达所致疾病的治疗药物中的应用。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2022/078934 WO2022184119A1 (zh) | 2021-03-04 | 2022-03-03 | 酪氨酸激酶抑制剂及其药物应用 |
US17/944,395 US20230043449A1 (en) | 2021-03-04 | 2022-09-14 | Tyrosine kinase inhibitors and pharmaceutical application thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110237399.5A CN113264888A (zh) | 2021-03-04 | 2021-03-04 | 酪氨酸激酶抑制剂及其药物应用 |
CN2021102373995 | 2021-03-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114394942A true CN114394942A (zh) | 2022-04-26 |
Family
ID=77228257
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110237399.5A Pending CN113264888A (zh) | 2021-03-04 | 2021-03-04 | 酪氨酸激酶抑制剂及其药物应用 |
CN202210197875.XA Pending CN114394942A (zh) | 2021-03-04 | 2022-03-02 | 酪氨酸激酶抑制剂及其药物应用 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110237399.5A Pending CN113264888A (zh) | 2021-03-04 | 2021-03-04 | 酪氨酸激酶抑制剂及其药物应用 |
Country Status (3)
Country | Link |
---|---|
US (1) | US20230043449A1 (zh) |
CN (2) | CN113264888A (zh) |
WO (1) | WO2022184119A1 (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113264888A (zh) * | 2021-03-04 | 2021-08-17 | 江苏康可得生物技术股份有限公司 | 酪氨酸激酶抑制剂及其药物应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108779079A (zh) * | 2016-01-06 | 2018-11-09 | 特里乌姆治疗公司 | 作为egfr抑制剂的新的氟化喹唑啉衍生物 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102382106A (zh) * | 2010-08-30 | 2012-03-21 | 黄振华 | 苯胺取代的喹唑啉衍生物 |
CN102898386B (zh) * | 2011-07-27 | 2015-07-29 | 上海医药集团股份有限公司 | 喹唑啉衍生物、其制备方法、中间体、组合物及其应用 |
CN104910140A (zh) * | 2014-03-14 | 2015-09-16 | 齐鲁制药有限公司 | 喹唑啉类化合物、其制备方法及应用 |
CN105646375A (zh) * | 2016-01-28 | 2016-06-08 | 哈尔滨医科大学 | 具有抗肿瘤活性的表皮生长因子受体酪氨酸激酶抑制剂nxgf和nxgh及其制备方法和应用 |
TW202012391A (zh) * | 2018-07-04 | 2020-04-01 | 日商第一三共股份有限公司 | 二芳基醚型喹唑啉衍生物 |
CN113264888A (zh) * | 2021-03-04 | 2021-08-17 | 江苏康可得生物技术股份有限公司 | 酪氨酸激酶抑制剂及其药物应用 |
-
2021
- 2021-03-04 CN CN202110237399.5A patent/CN113264888A/zh active Pending
-
2022
- 2022-03-02 CN CN202210197875.XA patent/CN114394942A/zh active Pending
- 2022-03-03 WO PCT/CN2022/078934 patent/WO2022184119A1/zh active Application Filing
- 2022-09-14 US US17/944,395 patent/US20230043449A1/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108779079A (zh) * | 2016-01-06 | 2018-11-09 | 特里乌姆治疗公司 | 作为egfr抑制剂的新的氟化喹唑啉衍生物 |
Non-Patent Citations (1)
Title |
---|
RICCARDO CASTELLI,ET AL.: "Balancing reactivity and antitumor activity: heteroarylthioacetamide derivatives as potent and time-dependent inhibitors of EGFR", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 162, 31 December 2019 (2019-12-31), pages 507 - 524, XP085568920, DOI: 10.1016/j.ejmech.2018.11.029 * |
Also Published As
Publication number | Publication date |
---|---|
US20230043449A1 (en) | 2023-02-09 |
WO2022184119A1 (zh) | 2022-09-09 |
CN113264888A (zh) | 2021-08-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Azizmohammadi et al. | 2H-chromene derivatives bearing thiazolidine-2, 4-dione, rhodanine or hydantoin moieties as potential anticancer agents | |
DK2880035T3 (en) | Hitherto UNKNOWN PYRROLOPYRIMIDINE COMPOUNDS AS PROTEIN CHINAS INHIBITORS | |
EP3061747B1 (en) | Pyridic ketone derivatives, method of preparing same, and pharmaceutical application thereof | |
EP3323817B1 (en) | Aniline pyrimidine derivatives and uses thereof | |
WO2009114993A1 (zh) | 一类哒嗪酮类化合物及其制备方法和用途 | |
EP2896620A1 (en) | Alkynyl heteroaromatic ring compound and application thereof | |
CN108101926B (zh) | 含喹啉酮的嘧啶并五元杂环类化合物、制备方法及其应用 | |
CN114394942A (zh) | 酪氨酸激酶抑制剂及其药物应用 | |
CN104829613B (zh) | 二芳基取代的吡唑并环类衍生物、其制备方法及其在医药领域的应用 | |
CN114292259A (zh) | 4-氨基酸侧链取代的喹唑啉衍生物及其应用 | |
JP6612882B2 (ja) | プテリジンジオンモノカルボン酸トランスポータ阻害薬 | |
CN109053594B (zh) | 1-(3,5-二甲氧基苯基)-3-(取代嘧啶-4-基)脲类化合物及其制备和应用 | |
CN111718325A (zh) | 一种2,4,5-取代嘧啶类化合物及其制备方法和应用 | |
CN110240598A (zh) | 甲酰胺衍生物的制备方法及其中间体化合物 | |
CN111675647B (zh) | 2-吲哚酮类pak1抑制剂及其在抗肿瘤治疗药物中的应用 | |
JP2011111433A (ja) | ウレイド構造を有するウラシル化合物又はその塩 | |
CN117580836A (zh) | 一种嘧啶并环结构衍生物及其用途 | |
CN103906751A (zh) | 作为晚期SV40因子(LSF)抑制剂用于治疗癌症的[1,3]二氧杂环戊烯并[4,5-g]喹啉-6(5H)-硫酮和[1,3]二氧杂环戊烯并[4,5-g][1,2,4]***并[1,5-a]喹啉衍生物 | |
CN111892536B (zh) | 取代的喹啉甲酰胺类化合物及其用途 | |
CN112759564B (zh) | 二芳基脲类化合物及其制法和药物用途 | |
WO2017049711A1 (zh) | 喹啉类衍生物、其药物组合物、制备方法及应用 | |
CN113891749A (zh) | 喹啉衍生物及其用于治疗癌症的用途 | |
CN111039941A (zh) | 一种含氮杂环化合物、其制备方法及应用 | |
CN115073460B (zh) | 一种嘧啶并[5,4-c][2,6]萘啶衍生物及其制备方法以及药物组合物和应用 | |
CN114957252B (zh) | 一种化合物及其制备方法以及药物组合物和在制备eed抑制剂中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |